Cargando…

Monoclonal antibody therapy for prevention of severe disease in nosocomial COVID-19

Background: In November 2020, the FDA issued an emergency use authorization (EUA) for monoclonal antibodies (mAbs) to be used in outpatients with COVID-19 infections who are at a high risk of progressing to severe disease. However, becuase the EUA had limited indications for inpatients, data on thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimilover, Adam, Doan, Thien-Ly, Jain, Sumeet, Malhotra, Prashant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614892/
http://dx.doi.org/10.1017/ash.2022.123